Biomarker assays might be letting down the precision oncology team due to a lack of standardisation between tests, platforms and positivity thresholds, pathologists say. According to a Comment article in the Lancet Oncology, the current FDA process of approving drugs with the companion diagnostics used in clinical trials isn’t always helping with consistency of biomarker ...
Lack of consistent biomarker assays may lead to ‘imprecision’ oncology
By Mardi Chapman
27 Oct 2020